We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke (CoBIS 2)

This study is currently recruiting participants.
Verified September 2017 by Joanne Kurtzberg, MD, Duke University Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT03004976
First Posted: December 29, 2016
Last Update Posted: September 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
The Marcus Foundation
Emory University
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Joanne Kurtzberg, MD, Duke University Medical Center
  Purpose
The primary objective of this study is to determine the efficacy of a single intravenous infusion of unrelated donor umbilical cord blood (UCB) for improving functional outcomes in patients with ischemic stroke. Eligible subjects will receive an intravenous infusion of UCB or placebo 3-10 days following stroke. Subjects will not receive immunosuppressive or myeloablative medications prior to the infusion. Subjects will be followed for one year post infusion for safety and efficacy. Assessments will examine safety and tolerability of the infusion, change in neurological symptoms, change in quality of life, and emotional and cognitive status. Assessments will occur at 24 hours post infusion, and at 30, 90, 180 and 365 days post infusion.

Condition Intervention Phase
Stroke Stroke, Acute Brain Injury, Acute Biological: Umbilical Cord Blood Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke - CoBIS 2

Further study details as provided by Joanne Kurtzberg, MD, Duke University Medical Center:

Primary Outcome Measures:
  • Shift in modified Rankin Scale (mRS) [ Time Frame: 3 months post infusion ]
    shift in modified Rankin Scale (mRS) from baseline to 3 months post infusion.


Secondary Outcome Measures:
  • Incidence and severity of infusion reactions [ Time Frame: 1 year post infusion ]
    Incidence and severity of infusion reactions

  • Incidence and severity of product-related infections [ Time Frame: 1 year post infusion ]
    Incidence and severity of product-related infections

  • Incidence of alloimmunization [ Time Frame: 1 year post infusion ]
    Incidence of alloimmunization

  • Incidence and severity of graft vs. host disease [ Time Frame: 1 year post infusion ]
    Incidence and severity of graft vs. host disease

  • Incidence and severity of study related and unexpected AEs [ Time Frame: 1 year post infusion ]
    Incidence and severity of study related and unexpected AEs

  • Mortality [ Time Frame: 1 year post infusion ]
    Mortality

  • Functional independence [ Time Frame: 90 days post infusion ]
    Functional independence at 90 days defined as a 90-day mRS score of 0, 1, or 2

  • mRS shift [ Time Frame: 30 days post infusion ]
    shift in mRS score between baseline and day 30

  • mRS shift [ Time Frame: 180 days post infusion ]
    shift in mRS score between baseline and day 180

  • NIHSS [ Time Frame: 90 days post infusion ]
    The National Institutes of Health Stroke Scale (NIHSS) score at 90 days

  • Barthel Index [ Time Frame: 90 days post infusion ]
    The Barthel Index (BI) score at 90 days

  • Stroke Impact Scale [ Time Frame: 90 days post infusion ]
    Stroke Impact Scale-16 (SIS-16) score at 90 days

  • European Quality of Life [ Time Frame: 90 days post infusion ]
    The European Quality of Life (EQ-5D-3L) survey score at 90 days

  • Patient Health Questionnaire Scale [ Time Frame: 90 days post infusion ]
    Patient Health Questionnaire Scale (PHQ 8) score at 90 days

  • Telephone Interview for Cognitive Status [ Time Frame: 30 days post infusion ]
    Telephone Interview for Cognitive Status (TICS) total score at 30 days post infusion

  • Telephone Interview for Cognitive Status [ Time Frame: 1 year post infusion ]
    Telephone Interview for Cognitive Status (TICS) total score at 1 year post infusion

  • Trail Making Test [ Time Frame: 90 days post infusion ]
    Trail Making Test score at 90 days post infusion

  • Montreal cognitive Assessment (MoCA) [ Time Frame: 90 days post infusion ]
    Montreal cognitive Assessment score at 90 days post infusion

  • Hopkins Verbal Learning Test-Revised (HVLT-R) [ Time Frame: 90 days post infusion ]
    Hopkins Verbal Learning Test-Revised score at 90 days post infusion

  • Patient Health Questionnaire (PHQ-8) [ Time Frame: 90 days post infusion ]
    Patient Health Questionnaire score at 90 days post infusion

  • Short Form 36 Health Survey (SF-36) [ Time Frame: 90 days post infusion ]
    Short Form 36 Health Survey score at 90 days post infusion

  • Controlled Oral Word Association test (COWAT) [ Time Frame: 90 days post infusion ]
    Controlled Oral Word Association Test score at 90 days post infusion

  • Oral Symbol Digit Modalities Test (SDMT) [ Time Frame: 90 days post infusion ]
    Oral Symbol Digit Modalities Test score at 90 days post infusion


Estimated Enrollment: 100
Actual Study Start Date: March 14, 2017
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Umbilical Cord Blood
A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
Biological: Umbilical Cord Blood
Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10^7 TNCC/kg.
Other Name: cord blood, hematopoietic stem cells
Placebo Comparator: Placebo
A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
Other: Placebo
The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 [pink]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.

Detailed Description:

This is a multicenter, placebo controlled, randomized, double blinded Phase 2 study in 100 subjects 18-90 years of age who have sustained a recent ischemic stroke. Potential subjects can be screened and consented the day of their stroke (Day 1). Treatment with umbilical cord blood (UCB) cells or placebo will be administered intravenously as a single infusion as early as 3 days but no later than 10 days after the patient's stroke. UCB units will be selected from an accredited U.S. public cord bank based on blood type, race and a targeted cell dose ranging between 0.5 to 5 x 10^7 total nucleated cell count (TNCC)/kg. Study subjects will not receive immunosuppressive or myeloablative medications prior to infusion of the cord blood or placebo.

All subjects, families and medical staff will be blinded to treatment arm. When a subject is randomized to study drug at a clinical site without a cord blood bank, the selected cord blood units (CBU) will be shipped frozen overnight to the site. Once selected and available on site, each CBU will be thawed, washed, tested, released and infused intravenously using common standard operating procedures (SOPs) at all sites. For subjects randomized to placebo, a diluent with the same appearance and odor as a CBU will be prepared.

Patients will have baseline magnetic resonance imaging (MRI) and will be assessed at 1, 3, 6, and 12 months for functional outcomes. All patients will receive standard of care therapy while enrolled in this study and all subjects will be strongly encouraged to participate in rehabilitative therapy.

The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows:

  1. To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke
  2. To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke
  3. To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-90 years old
  2. Recent, acute, cortical, hemispheric, ischemic stroke in the MCA distribution without a clinically significant midline shift as detected by MRI as a DWI abnormality
  3. NIHSS 6-15 (R) and 6-18 (L) at the time of enrollment with no more than 4 point increase (worsening of score) from baseline score to 24 hours prior to infusion
  4. Subjects must have a platelet count >100,000/µL, hemoglobin >8mg/dL, absolute lymphocyte count (ALC) ≥ 1500, and WBC >2,500/µL
  5. Subjects who received tPA or underwent endovascular reperfusion may be included in the study
  6. Able to provide consent to study or consent is obtained from the patient's legal representative
  7. Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the Investigator, they will not become pregnant during the course of the study
  8. Is a good candidate for the trial, in the opinion of the Investigator
  9. Agrees to participate in follow-up visits
  10. ABO/Rh and race matched CBU(s) with a minimum of 0.5 x 10^7 TNCC/kg based on the pre-cryopreservation TNCC is available for infusion
  11. Has not had a disease or therapy that would compromise current immune function.

Exclusion Criteria:

An individual is ineligible to participate if any of the following apply:

Exclusionary Medical Conditions:

  1. Medical history of neurological or orthopedic pathology with a deficit as a consequence that results in a modified Rankin Scale >1 before stroke or has a pre existing cognitive deficit
  2. Clinically significant and/or symptomatic hemorrhage associated with stroke
  3. Evidence of significant midline shift as assessed by CT or MRI who are felt to be at high risk for neurological decompensation or need for decompressive hemicraniectomy due to hemispheric edema
  4. New intracranial hemorrhage, edema, or mass effect that may place patient at increased risk for secondary deterioration when assessed prior to infusion
  5. Hypotension as defined as the need for IV pressor support of SBP <90
  6. Isolated brain stem stroke
  7. Pure lacunar stroke
  8. Requires mechanical ventilation. An exception may be patients who were electively intubated for endovascular reperfusion and then extubated immediately following the procedure.
  9. Requires a craniotomy
  10. Serious psychiatric or neurological disease which could alter evaluation on functional or cognitive scales
  11. Active systemic infection that is felt, at the discretion of the Investigator, to place the patient at increased risk for participation in this study
  12. Documentation of human immunodeficiency virus positive (HIV+) status in the medical record
  13. Active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma
  14. Known hypercoagulable state or coagulopathy deficiencies such as Factor V Leiden, Antiphospholipid Syndrome (APC), Protein C, Protein S, anticardiolipin antibody, phospholipid syndrome or Sickle Cell Disease
  15. History of or currently active autoimmune disease, or current immunomodulatory therapy or a recipient of immunomodulatory therapy in the past year.
  16. Concurrent illness or condition that in the opinion of the Investigator might interfere with treatment or evaluation of safety
  17. Current or recent history of alcohol or drug abuse, or stroke associated with drug abuse that Investigator feels may impair therapy or assessments
  18. Pregnant as documented by blood test

Prohibited Concomitant or Prior Therapies

  1. Patients currently receiving immunosuppressant drugs, not including glucocorticoid taper, topical/inhaled glucocorticoids
  2. History of prior transfusion reaction
  3. Currently on dialysis
  4. Recipient of bone marrow or organ transplant
  5. Renal insufficiency with serum creatinine > 2.0 mg/dL
  6. Hepatic insufficiency (bilirubin >2.5mg/dL or transaminases >5x the ULN) Patients with Gilberts syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level
  7. Previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy
  8. Participating in another interventional clinical trial of an investigational therapy within 30 days of screening

Other Exclusion Criteria

  1. Pregnant or lactating women
  2. Unable or unwilling to be evaluated for follow-up visits
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004976


Contacts
Contact: Study Coordinator 919-684-3293 erin.arbuckle@dm.duke.edu

Locations
United States, Florida
University of Florida Health Shands Hospital Recruiting
Gainesville, Florida, United States, 32610
Contact: Teresa Lyles, PhD    352-294-5693    Teresa.Lyles@neurology.ufl.edu   
Principal Investigator: Nandakumar Nagaraja, MD         
United States, Georgia
Emory University School of Medicine Recruiting
Atlanta, Georgia, United States, 30303
Contact: Shannon Doppelheuer, CCRC    404-778-1034    sdoppelheuer@emory.edu   
Principal Investigator: Michael Frankel, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Ellen Bennet, PhD    919-668-1429    ellen.bennett@dm.duke.edu   
Principal Investigator: Daniel Laskowitz, MD         
United States, Texas
Houston Methodist Recruiting
Houston, Texas, United States, 77030
Contact: Jonathan Wiese, MSN, RN, CNL    713-441-7161    jrwiese@houstonmethodist.org   
Principal Investigator: John J Volpi, MD         
Sponsors and Collaborators
Joanne Kurtzberg, MD
The Marcus Foundation
Emory University
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Joanne Kurtzberg, MD Duke University
  More Information

Responsible Party: Joanne Kurtzberg, MD, Director, Robertson Clinical and Translational Cell Therapy Program, Duke University Medical Center
ClinicalTrials.gov Identifier: NCT03004976     History of Changes
Other Study ID Numbers: Pro00077580
First Submitted: November 30, 2016
First Posted: December 29, 2016
Last Update Posted: September 15, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Joanne Kurtzberg, MD, Duke University Medical Center:
hematopoietic stem cells
umbilical cord blood
stroke
ischemic stroke

Additional relevant MeSH terms:
Stroke
Brain Injuries
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries